CT-G32 / Celltrion - LARVOL DELTA

Celltrion steps into weight-loss market with oral rival to Wegovy, Mounjaro (KED Global) - "The company announced on Wednesday that it is developing CT-G32, an orally administered quadruple-receptor agonist designed to activate four metabolic pathways simultaneously, an approach that would move beyond the GLP-1 and dual-agonist injections, like Wegovy and Mounjaro, that dominate the global obesity drug market....Patent registrations have been completed, and formal preclinical development is planned for 2026."

New molecule • Patent • Preclinical • Obesity